VeriTeQ Corporation Appoints New Chief Legal and Financial Officer

VeriTeQ Corporation, a provider of implantable medical device identification and radiation dose measurement technologies, has appointed Michael Krawitz as its Chief Legal and Financial Officer.  
Former Chief Financial Officer Lorraine Breece will remain with the company in a different capacity, though executives did not detail her new role.

Krawitz most recently was CEO of Pear Energy, a renewable energy company that finances renewable energy and energy efficiency projects. He has worked previously with VeriTeQ Chairman/CEO Scott R. Silverman, most recently as a board member for the company. Krawitz earned a bachelor of arts degree from Cornell University and a juris doctorate from Harvard Law School.

“Now that the commercial launch of our products is underway and we are becoming more active in the capital markets with a goal of a future up-listing, Michael’s public company and legal expertise will greatly benefit VeriTeQ,” said Silverman. “We are very fortunate that Michael will help deepen our executive team to help us execute our plan and develop our business.”

“VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a great example of what VeriTeQ does with all of its products—using technology to give doctors, nurses and patients more accurate information, leading to better treatment and fewer mistakes,” Krawitz said. “I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes, thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to grow VeriTeQ.”

VeriTeQ develops proprietary RFID technologies for implantable medical device identification and dosimeter technologies for use in radiation therapy treatment. The Delray Beach, Fla., firm offers a U.S. Food and Drug Administration-cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.